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The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus 
 
Marc Y Donath and Thomas Mandrup-Poulsen 
 
Decreased functional islet [beta]-cell mass is the main cause of onset and progression of 
both type 1 and 2 diabetes mellitus. In type 1 diabetes mellitus, [beta]-cell death is 
predominantly due to an autoimmune-driven, T-cell-mediated inflammatory process in 
the islets.1 Although the mechanisms of [beta]-cell failure in type 2 diabetes mellitus 
remain debated, stress and inflammatory pathways have been implicated. For example, 
metabolic stress caused by repetitive glucose excursions, dyslipidemia and adipokines1 
can induce an inflammatory response characterized by local cytokine secretion,2 islet 
immune-cell infiltration,3 [beta]-cell apoptosis, amyloid deposits, and eventual fibrosis. 
Thus, islet inflammation could be a shared feature of both types of diabetes mellitus, 
converging on a common pathway that leads to [beta]-cell secretory failure and 
apoptosis. In this context, interleukin-1[beta] (IL-1[beta]) has emerged as a master 
cytokine, which regulates islet chemokine production and causes impaired insulin 
production and [beta]-cell death.4 Preclinical studies of IL-1 antagonism in animal 
models of both type 1 and type 2 diabetes mellitus have shown promising results.1 In 
this Viewpoint, we discuss the potential role of anakinra—a recombinant human IL-1-
receptor antagonist—in the treatment of diabetes mellitus.  
Anakinra is a competitive inhibitor of IL-1 binding to type I IL-1 receptors.5 This 
agent is currently licensed for the treatment of rheumatoid arthritis unresponsive to other 
disease-modifying antirheumatic drugs. As IL-1[beta] clearly has a key role in the 
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pathogenesis of diabetes mellitus, the availability of anakinra allowed us to conduct a 
clinical trial of IL-1 receptor antagonism in patients with type 2 diabetes mellitus.6 
In our study, 70 patients were randomly allocated to receive either receive 
placebo or a subcutaneous injection of 100 mg anakinra once daily for 13 weeks. At 
study end, the HbA1c level was lower in the anakinra-treated group than in the placebo 
group (between-group difference 0.46%, 95% CI 0.01–0.90%; P = 0.03). Importantly, 
[beta]-cell secretory function was enhanced by treatment with anakinra and the 
proinsulin-to-insulin ratio (an indicator of [beta]-cell stress) was reduced. A marked 
reduction of systemic inflammation as reflected by decreased serum IL-6 and C-reactive 
protein levels was also observed. Interestingly, however, insulin resistance, insulin-
regulated gene expression in skeletal muscle, serum adipokine levels, and BMI were all 
unaffected. Symptomatic hypoglycemia and other apparent drug-related serious adverse 
events were not observed, in line with the well-documented favorable safety profile of IL-
1 antagonism in patients with rheumatoid arthritis. Our study, therefore, represents the 
first proof-of-principle that IL-1 antagonism has therapeutic potential in the treatment of 
diabetes mellitus. 
Levels of acute-phase proteins are elevated in patients with type 2 diabetes 
mellitus and chronic low-grade inflammation might play a pathogenetic role in this 
condition.1,7 Elevated levels of IL-1[beta] and IL-6 confer an increased risk for 
developing type 2 diabetes mellitus.8 Many studies have demonstrated an association 
between markers of systemic inflammation and insulin resistance (but not insulin 
secretion).7 Unfortunately, however, intervention studies targeting TNF, IL-6 and IL-1  by 
specific antibodies or receptor antagonism have failed to show any effect on insulin 
resistance.1,6 Possibly, circulating cytokines might origin predominantly from  
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inflammatory lesions in the vessel wall and may not reflect  the activity of the 
inflammatory process in adipose tissues. It should be noted, however, that cytokines act 
in networks, and that implementation of a more-potent inhibition or production of a 
general inflammatory blockade by antagonization of several cytokines could be needed 
to affect insulin sensitivity. Nonetheless, the marked decrease in systemic inflammation 
observed with anakinra could represent an added treatment benefit for cardiovascular 
disease associated with diabetes mellitus. The effects of anakinra on cardiovascular 
disease will, therefore, be assessed in future studies. 
The clinical relevance of our trial has been questioned because of the seemingly 
modest change in HbA1c levels. Anakinra has a short half-life of 4–6 h and is a weak 
antagonist that requires a 500-fold molar excess to block IL-1 action. As the patients 
enrolled in our study were overweight or obese (BMI >27 kg/m2), it is likely that they 
were under dosed. The FDA-approved dose of anakinra for rheumatoid arthritis is 100 
mg per day and so was the only dose ethically justifiable for this proof-of-concept study. 
Accordingly, changes in HbA1c levels in anakinra-treated patients correlated negatively 
with baseline BMI and body surface area as surrogates of anakinra drug-distribution 
volume. 
When patients in our study were stratified into tertiles according to body surface 
area, the improvement in HbA1c was 0.84% in the lowest tertile, comparable to that 
observed with glucagon-like peptide-1-based therapies. Notably, a 1% absolute 
reduction in the HbA1c level is associated with a 21% lower relative risk for developing 
late diabetic complications.9 Dose-escalation could, therefore, result in a clinically 
meaningful reduction in HbA1c levels in very obese patients. The patients included in our 
study had long-term duration of diabetes mellitus, and most were treated with oral 
NATURE - Clin Pract Endocrinol Metab. In Press 
 
4
antidiabetic agents alone or in combination with insulin. Drug-naïve patients with recent 
onset of disease might, therefore, benefit more from treatment with anakinra. 
Can the improved glycemia caused by IL-1 antagonism be explained by a 
discrete change in insulin sensitivity undetectable by euglycemic hyperinsulinemic 
clamp? For example, an improvement in hepatic insulin sensitivity offset by a worsening 
of insulin action in muscle,  resulting in an increment in [beta]-cell function. It is difficult to 
envisage how unchanged whole-body insulin sensitivity would physiologically signal an 
increased [beta]-cell secretory response and so lead to an appreciable reduction in 
glycemia. Furthermore, anakinra markedly improved the proinsulin-to-insulin ratio, did 
not change insulin-regulated gene expression in skeletal muscle, and did not affect the 
levels of circulating adipokines. Several lines of evidence from our study, therefore, 
clearly support a direct improvement of [beta]-cell secretory function by anakinra. 
Increased apoptosis is the major defect that leads to decreased [beta]-cell mass 
in patients with diabetes mellitus.10 Novel therapeutic approaches designed to inhibit cell 
death could be a key development in the management of diabetes mellitus, possibly in 
combination with agents with [beta]-cell regenerative potential such as glucagon-like 
peptide-1. Rather than just palliate glycemia, IL-1 antagonism might represent a novel 
and realistic treatment principle directed against the causal pathogenetic processes that 
underlie diabetes mellitus, whereby the progressive decline in functional [beta]-cell 
mass, insulin resistance and angiopathy could be prevented or even reversed. IL-1 
antagonism has potential as a disease-modifying agent in diabetes mellitus. Although 
the autoinflammatory feature of type 2 diabetes mellitus might be successfully 
antagonized by targeting IL-1[beta] alone, the autoimmune component of type 1 
diabetes mellitus could require combination therapy (e.g. with anti-CD3 antibodies). 
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Future studies should also evaluate the clinical benefit of IL-1 antagonists with 
prolonged half-lives that allow weekly or monthly injection schedules. 
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